Zemaira

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Zemaira
Generic name
ALPHA-1-PROTEINASE INHIBITOR HUMAN
Manufacturer
CSL Behring LLC
Product type
PLASMA DERIVATIVE
SPL set ID
0c3354b5-a1d8-4f98-ad55-2eafe4265c4e
SPL ID
a60040d6-46ed-4a3b-af7e-528a65b7fca7
Version
27
Effective date
2024-09-23
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:19

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Observe any signs of hypersensitivity such as tachycardia, hypotension, confusion, syncope, oxygen consumption decrease, and pharyngeal edema when administering ZEMAIRA to patients with known hypersensitivity to an A 1 -PI product ( 5.1 ). Patients with selective or severe IgA deficiency can develop antibodies to IgA and, therefore, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately ( 5.2 ). Because ZEMAIRA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent ( 5.3 ). 5.1 Hypersensitivity to Other A 1 -PI Products Observe any signs of hypersensitivity such as tachycardia, hypotension, confusion, syncope, oxygen consumption decrease, and pharyngeal edema when administering ZEMAIRA to patients with known hypersensitivity to an A 1 -PI product. If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately. Have epinephrine and other appropriate supportive therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction. 5.2 Hypersensitivity to IgA ZEMAIRA may contain trace amounts of IgA. Patients with selective or severe IgA deficiency can develop antibodies to IgA and, therefore, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately. Have epinephrine and other appropriate supportive therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction. ZEMAIRA is contraindicated in IgA-deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity. 5.3 Transmissible Infectious Agents Because ZEMAIRA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for ZEMAIRA [see Description (11) ] . Despite these measures, ZEMAIRA, like other products made from human blood, may still potentially contain human pathogenic agents, including those not yet known or identified. Thus, the risk of transmission of infectious agents cannot be totally eliminated. All infections thought by a physician to have been possibly transmitted by this product should be reported by the physician or other healthcare provider to the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 5 matching rows.

adverse reactions

6 ADVERSE REACTIONS Serious adverse reactions reported following administration of ZEMAIRA in pre-licensure clinical trials included one event each in separate subjects of bronchitis and dyspnea, and one event each in a single subject of chest pain, cerebral ischemia and convulsion. The most common adverse reactions (ARs) occurring in at least 5% of subjects receiving ZEMAIRA in all pre-licensure clinical trials were headache, sinusitis, upper respiratory infection, bronchitis, asthenia, cough increased, fever, injection site hemorrhage, rhinitis, sore throat, and vasodilation. Serious adverse reactions identified during postmarketing use were hypersensitivity reactions [see Warnings and Precautions (5.1) ] . In post-licensure trials, the exposure adjusted incidence rate (EAIR) of serious exacerbations of chronic obstructive pulmonary disease (COPD) among subjects was higher during the RAPID Extension trial as compared to the rate observed during the preceding RAPID trial [see Adverse Reactions (6.1) ] . Serious adverse reactions reported following administration of ZEMAIRA in pre-licensure clinical trials included one event each in separate subjects of bronchitis and dyspnea, and one event each in a single subject of chest pain, cerebral ischemia and convulsion. The most common adverse reactions occurring in at least 5% of subjects receiving ZEMAIRA in all pre-licensure clinical trials were headache, sinusitis, upper respiratory infection, bronchitis, asthenia, cough increased, fever, injection site hemorrhage, rhinitis, sore throat, and vasodilation ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice . The following clinical trials were conducted with ZEMAIRA: Controlled, double-blind trial in 44 subjects, who received a weekly 60 mg/kg body weight dose of either ZEMAIRA (30 subjects) or Prolastin ® (a commercially available Alpha 1 -Proteinase Inhibitor [Human] product) (14 subjects) for 10 weeks, followed by an open-label phase in which 43 subjects received ZEMAIRA weekly for 14 weeks; Open-label trial in 9 subjects who received a weekly 60 mg/kg body weight dose of ZEMAIRA for 26 weeks, followed by a 7-week to 22-week extension; Crossover, double-blind trial in 18 subjects who received a single 60 mg/kg dose of ZEMAIRA and a single 60 mg/kg dose of Prolastin; Open-label trial of 19 subjects who received a single 15 mg/kg (2 subjects), 30 mg/kg (5 subjects), 60 mg/kg (6 subjects), or 120 mg/kg (6 subjects) dose of ZEMAIRA; and Post-Licensure Randomized, Placebo-Controlled Trial of Augmentation Therapy in Alpha-1 Protease Inhibitor Deficiency (RAPID), in 180 subjects who received a weekly 60 mg/kg body weight dose of either ZEMAIRA (93 subjects) or placebo (87 subjects) for 24 months (referred to as years 1 and 2 in Table 3). Post-Licensure Open-label extension of the RAPID trial involving 140 subjects who had completed blinded treatment with ZEMAIRA or placebo for 24 months in the RAPID trial and who entered the extension trial and received open-label ZEMAIRA for up to an additional 24 months (referred to as years 3 and 4 in Table 3). Table 1 summarizes the ARs, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in pre-licensure clinical trials of ZEMAIRA. Table 1. Overall Adverse Reactions (ARs) and Serious ARs Number of Subjects Based on unique subjects. If a subject experienced more than one AR, the subject was only counted once. (Events per Subject-Year The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database. ) Number of Infusions If there were multiple occurrences of ARs following a single infusion, only one occurrence was counted. (% of all Infusions) ZEMAIRA (n=66, SY SY=subject-year. =28.72) Prolastin (n=32), SY =3.83) ZEMAIRA (n=1296) Prolastin (n=160) ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). 54 (5.6) 16 (3.8) 160 (12.3) 31 (19.4) Serious ARs (Serious AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). 4 (0.2) 1 (1.0) 6 (0.5) 1 (0.6) Table 2 summarizes the ARs occurring in 5% or more (>3) subjects, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in clinical trials of ZEMAIRA. Table 2. Adverse Reactions Occurring in ≥5% of Subjects ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). Number of Subjects Based on unique subjects. If a subject experienced more than one AR of the same type, the subject was only counted once. (Events per Subject-Year The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database. ) Number of Infusions If more than one of the same type of an event occurred after an infusion, only one event was counted. (% of all Infusions) ZEMAIRA (n=66, SY SY=subject-year. =28.72) Prolastin (n=32, SY =3.83) ZEMAIRA (n=1296) Prolastin (n=160) Headache 13 (0.7) 5 (1.3) 19 (1.5) 5 (3.1) Sinusitis 10 (0.5) 1 (0.3) 13 (1.0) 1 (0.6) Upper Respiratory Infection 10 (0.4) 1 (0.3) 10 (0.8) 1 (0.6) Bronchitis 5 (0.2) 0 (0.0) 6 (0.5) 0 (0.0) Asthenia 5 (0.2) 2 (0.5) 5 (0.4) 2 (1.3) Cough Increased 5 (0.2) 1 (0.5) 5 (0.4) 2 (1.3) Fever 4 (0.1) 0 (0.0) 4 (0.3) 0 (0.0) Injection Site Hemorrhage 4 (0.1) 0 (0.0) 4 (0.3) 0 (0.0) Rhinitis 4 (0.1) 0 (0.0) 4 (0.3) 0 (0.0) Sore Throat 4 (0.1) 0 (0.0) 4 (0.3) 0 (0.0) Vasodilation 4 (0.1) 1 (0.3) 4 (0.3) 1 (0.6) Diffuse interstitial lung disease was noted on a routine chest x-ray of one subject at Week 24. Causality could not be determined. Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In a retrospective analysis, during the 10-week blinded portion of the 24-week clinical trial, 6 subjects (20%) of the 30 treated with ZEMAIRA had a total of 7 exacerbations of their chronic obstructive pulmonary disease (COPD). Nine subjects (64%) of the 14 treated with Prolastin had a total of 11 exacerbations of their COPD. The observed difference between groups was 44% (95% confidence interval [CI] from 8% to 70%). Over the entire 24-week treatment period, of the 30 subjects in the ZEMAIRA treatment group, 7 subjects (23%) had a total of 11 exacerbations of their COPD. In the RAPID study 25 serious exacerbations of COPD were reported in 15 ZEMAIRA subjects vs. 17 such events in 9 placebo subjects, corresponding to rates of 0.146 exacerbations per subject-year with ZEMAIRA and 0.115 exacerbations per subject-year with placebo, (ratio ZEMAIRA:Placebo [95% confidence interval]: 1.256 [0.457 - 3.454]). Subjects who were randomized to ZEMAIRA in the 2-year RAPID trial who then entered and received open-label ZEMAIRA in the 2 year RAPID extension trial were in the "Early Start" group. Subjects who were randomized to Placebo in the 2-year RAPID trial who then entered and received open-label ZEMAIRA in the 2 year RAPID extension trial were in the "Delayed Start" group. During the RAPID Extension trial 37 serious exacerbations of COPD were reported in 19 subjects (25%) in the Early Start group, corresponding to rates of 0.25 exacerbations per subject-year. In comparison, 20 serious exacerbations were reported in 11 subjects (17%) in the Delayed Start group corresponding to rates of 0.16 exacerbations per subject-year (ratio Early: Delayed [95% confidence interval]: 1.58 [0.68 – 3.66], Table 3). Among the Early Start subjects who entered the RAPID extension trial (N = 76), the exposure adjusted incidence rate of serious exacerbations during the RAPID extension trial (years 3-4) was 0.25 compared to 0.12 for those subjects during the earlier RAPID trial (years 1-2), (ratio RAPID Extension:RAPID: 2.10 [95% confidence interval: 1.21 – 3.67]). Among the Delayed Start subjects who entered the RAPID extension trial (N = 64), the exposure adjusted incidence rate of serious exacerbations during the RAPID extension trial (years 3-4) was 0.16 compared to 0.10 for those subjects during the earlier RAPID trial (years 1-2), (ratio RAPID Extension:RAPID: 1.56 [95% confidence interval: 0.80 – 3.03]). Table 3. Comparison of Exposure-Adjusted Incidence Rates (EAIR) for Serious COPD Exacerbations Occurring in the RAPID study between ZEMAIRA and Placebo subjects and in the RAPID Extension Studies between Early Start and Delayed Start subjects Serious COPD Exacerbations Episode = Serious exacerbations of COPD identified by investigators as meeting the Anthonisen criteria 1 plus Serious Adverse Event (SAE) terms COPD, Condition Aggravated, Bronchitis, Lower Respiratory Tract Infection, Pneumonia. Serious exacerbation events that overlap or occur within 1 day of one another were counted as single exacerbation episodes. Episode n % EAIR (95% CI) Episode n % EAIR 95% CI Treatment Ratio for EAIR (95% CI) N = total number of safety subjects, n = number of subjects within a category, % = (n/N)*100, CI = Confidence Interval. Subject time at risk: ZEMAIRA = 171.14 years, Placebo = 147.75 years, Early Start Group = 146.46 years, Delay Start Group = 124.71 years. EAIR = Exposure-Adjusted Incidence Rate (events/subject time at risk). The point estimates and confidence intervals for EAIR values were calculated using negative binomial models. RAPID Study (Years 1 – 2) ZEMAIRA (N = 93) Placebo (N = 87) ZEMAIRA: Placebo 25 15 16.1 0.15 (0.10-0.22) 17 9 10.3 0.12 (0.07-0.18) 1.26 (0.46 - 3.45) Extension Study (Years 3-4) Early Start Early Start Group subjects were randomized to ZEMAIRA during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4). (N = 76) Delayed Start Delayed Start Group subjects were randomized to Placebo during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4). (N = 64) Early: Delayed 37 19 25.0 0.25 (0.18 – 0.35) 20 11 17.2 0.16 (0.10 – 0.25) 1.58 (0.68 – 3.66) In the 24-week double-blind trial, ZEMAIRA-treated subjects were tested for HAV, HBV, HCV, HIV, and parvovirus B19 (B19V), and no evidence of virus transmission was observed. 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. No anti-A 1 PI antibodies have been detected in clinical trials of ZEMAIRA. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ZEMAIRA with the incidence of antibodies to other products may be misleading. 6.3 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Table 4 lists the ARs that have been identified during postmarketing use of ZEMAIRA. This list does not include reactions already reported in clinical trials with ZEMAIRA [see Adverse Reactions (6.1) ] . Table 4. ARs Reported During the Postmarketing Use of ZEMAIRA System Organ Class Preferred Term/Symptoms Blood and lymphatic system disorders Lymph node pain Gastrointestinal disorders Nausea General disorders and administration site conditions Chills, infusion site reactions, facial, periorbital, lip and extremity swelling, chest pain Nervous system disorders Hypoesthesia, paresthesia, dizziness Skin disorders Hyperhidrosis, pruritus, rash including exfoliative and generalized, urticaria Vascular disorders Flushing

adverse reactions table

<table width="85%"><caption>Table 1. Overall Adverse Reactions (ARs) and Serious ARs</caption><col width="24%" align="left" valign="top"/><col width="19%" align="center" valign="top"/><col width="19%" align="center" valign="top"/><col width="19%" align="center" valign="top"/><col width="19%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule" rowspan="2"/><th styleCode="Rrule" colspan="2" align="center">Number of Subjects<footnote>Based on unique subjects. If a subject experienced more than one AR, the subject was only counted once.</footnote> (Events per Subject-Year<footnote>The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database.</footnote>)</th><th styleCode="Rrule" colspan="2">Number of Infusions<footnote>If there were multiple occurrences of ARs following a single infusion, only one occurrence was counted.</footnote> (% of all Infusions)</th></tr><tr><th styleCode="Lrule Rrule" align="center">ZEMAIRA (n=66, SY<footnote ID="T1F4">SY=subject-year.</footnote>=28.72)</th><th styleCode="Rrule">Prolastin (n=32), SY<footnoteRef IDREF="T1F4"/>=3.83)</th><th styleCode="Rrule">ZEMAIRA (n=1296)</th><th styleCode="Rrule">Prolastin (n=160)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).</td><td styleCode="Rrule">54 (5.6)</td><td styleCode="Rrule">16 (3.8)</td><td styleCode="Rrule">160 (12.3)</td><td styleCode="Rrule">31 (19.4)</td></tr><tr><td styleCode="Lrule Rrule">Serious ARs (Serious AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).</td><td styleCode="Rrule">4 (0.2)</td><td styleCode="Rrule">1 (1.0)</td><td styleCode="Rrule">6 (0.5)</td><td styleCode="Rrule">1 (0.6)</td></tr></tbody></table>

adverse reactions table

<table width="85%"><caption>Table 2. Adverse Reactions Occurring in &#x2265;5% of Subjects</caption><col width="20%" align="left" valign="top"/><col width="20%" align="center" valign="top"/><col width="20%" align="center" valign="top"/><col width="20%" align="center" valign="top"/><col width="20%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule" rowspan="2">ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate).</th><th styleCode="Rrule" colspan="2">Number of Subjects<footnote>Based on unique subjects. If a subject experienced more than one AR of the same type, the subject was only counted once.</footnote> (Events per Subject-Year<footnote>The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database.</footnote>)</th><th styleCode="Rrule" colspan="2">Number of Infusions<footnote>If more than one of the same type of an event occurred after an infusion, only one event was counted.</footnote> (% of all Infusions)</th></tr><tr><th styleCode="Rrule" align="center">ZEMAIRA (n=66, SY<footnote ID="T2F4">SY=subject-year.</footnote>=28.72)</th><th styleCode="Rrule">Prolastin (n=32, SY<footnoteRef IDREF="T2F4"/>=3.83)</th><th styleCode="Rrule">ZEMAIRA (n=1296)</th><th styleCode="Rrule">Prolastin (n=160)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">13 (0.7)</td><td styleCode="Rrule">5 (1.3)</td><td styleCode="Rrule">19 (1.5)</td><td styleCode="Rrule">5 (3.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Sinusitis</td><td styleCode="Rrule">10 (0.5)</td><td styleCode="Rrule">1 (0.3)</td><td styleCode="Rrule">13 (1.0)</td><td styleCode="Rrule">1 (0.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Upper Respiratory Infection</td><td styleCode="Rrule">10 (0.4)</td><td styleCode="Rrule">1 (0.3)</td><td styleCode="Rrule">10 (0.8)</td><td styleCode="Rrule">1 (0.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Bronchitis</td><td styleCode="Rrule">5 (0.2)</td><td styleCode="Rrule">0 (0.0)</td><td styleCode="Rrule">6 (0.5)</td><td styleCode="Rrule">0 (0.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Asthenia</td><td styleCode="Rrule">5 (0.2)</td><td styleCode="Rrule">2 (0.5)</td><td styleCode="Rrule">5 (0.4)</td><td styleCode="Rrule">2 (1.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Cough Increased</td><td styleCode="Rrule">5 (0.2)</td><td styleCode="Rrule">1 (0.5)</td><td styleCode="Rrule">5 (0.4)</td><td styleCode="Rrule">2 (1.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Fever</td><td styleCode="Rrule">4 (0.1)</td><td styleCode="Rrule">0 (0.0)</td><td styleCode="Rrule">4 (0.3)</td><td styleCode="Rrule">0 (0.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Injection Site Hemorrhage</td><td styleCode="Rrule">4 (0.1)</td><td styleCode="Rrule">0 (0.0)</td><td styleCode="Rrule">4 (0.3)</td><td styleCode="Rrule">0 (0.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Rhinitis</td><td styleCode="Rrule">4 (0.1)</td><td styleCode="Rrule">0 (0.0)</td><td styleCode="Rrule">4 (0.3)</td><td styleCode="Rrule">0 (0.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Sore Throat</td><td styleCode="Rrule">4 (0.1)</td><td styleCode="Rrule">0 (0.0)</td><td styleCode="Rrule">4 (0.3)</td><td styleCode="Rrule">0 (0.0)</td></tr><tr><td styleCode="Lrule Rrule">Vasodilation</td><td styleCode="Rrule">4 (0.1)</td><td styleCode="Rrule">1 (0.3)</td><td styleCode="Rrule">4 (0.3)</td><td styleCode="Rrule">1 (0.6)</td></tr></tbody></table>

adverse reactions table

<table width="95%"><caption>Table 3. Comparison of Exposure-Adjusted Incidence Rates (EAIR) for Serious COPD Exacerbations Occurring in the RAPID study between ZEMAIRA and Placebo subjects and in the RAPID Extension Studies between Early Start and Delayed Start subjects</caption><col width="12%" align="center" valign="middle"/><col width="10%" align="center" valign="middle"/><col width="6%" align="center" valign="middle"/><col width="7%" align="center" valign="middle"/><col width="14%" align="center" valign="middle"/><col width="10%" align="center" valign="middle"/><col width="6%" align="center" valign="middle"/><col width="7%" align="center" valign="middle"/><col width="14%" align="center" valign="middle"/><col width="14%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule">Serious COPD Exacerbations<footnote ID="T3F1">Episode = Serious exacerbations of COPD identified by investigators as meeting the Anthonisen criteria<sup>1</sup> plus Serious Adverse Event (SAE) terms COPD, Condition Aggravated, Bronchitis, Lower Respiratory Tract Infection, Pneumonia. Serious exacerbation events that overlap or occur within 1 day of one another were counted as single exacerbation episodes.</footnote></th><th styleCode="Rrule">Episode</th><th styleCode="Rrule">n</th><th styleCode="Rrule">%</th><th styleCode="Rrule">EAIR (95% CI)</th><th styleCode="Rrule">Episode</th><th styleCode="Rrule">n</th><th styleCode="Rrule">%</th><th styleCode="Rrule">EAIR 95% CI</th><th styleCode="Lrule Rrule" valign="top">Treatment Ratio for EAIR (95% CI)<footnoteRef IDREF="T3F1"/></th></tr></thead><tfoot><tr><td colspan="10" align="left" valign="top">N = total number of safety subjects, n = number of subjects within a category, % = (n/N)*100, CI = Confidence Interval. Subject time at risk: ZEMAIRA = 171.14 years, Placebo = 147.75 years, Early Start Group = 146.46 years, Delay Start Group = 124.71 years. EAIR = Exposure-Adjusted Incidence Rate (events/subject time at risk). The point estimates and confidence intervals for EAIR values were calculated using negative binomial models.</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="2"><content styleCode="bold">RAPID Study (Years 1 &#x2013; 2)</content></td><td styleCode="Rrule" colspan="4"><content styleCode="bold">ZEMAIRA (N = 93)</content></td><td styleCode="Rrule" colspan="4"><content styleCode="bold">Placebo (N = 87)</content></td><td styleCode="Rrule Botrule"><content styleCode="bold">ZEMAIRA: Placebo</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">25</td><td styleCode="Rrule" valign="top">15</td><td styleCode="Rrule" valign="top">16.1</td><td styleCode="Rrule" valign="top">0.15 (0.10-0.22)</td><td styleCode="Rrule" valign="top">17</td><td styleCode="Rrule" valign="top">9</td><td styleCode="Rrule" valign="top">10.3</td><td styleCode="Rrule" valign="top">0.12 (0.07-0.18)</td><td styleCode="Rrule" valign="top">1.26 (0.46 - 3.45)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="2"><content styleCode="bold">Extension Study (Years 3-4)</content></td><td styleCode="Rrule" colspan="4"><content styleCode="bold">Early Start<footnote>Early Start Group subjects were randomized to ZEMAIRA during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4).</footnote> (N = 76)</content></td><td styleCode="Rrule" colspan="4"><content styleCode="bold">Delayed Start<footnote>Delayed Start Group subjects were randomized to Placebo during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4).</footnote> (N = 64)</content></td><td styleCode="Rrule"><content styleCode="bold">Early: Delayed</content></td></tr><tr><td styleCode="Rrule" valign="top">37</td><td styleCode="Rrule" valign="top">19</td><td styleCode="Rrule" valign="top">25.0</td><td styleCode="Rrule" valign="top">0.25 (0.18 &#x2013; 0.35)</td><td styleCode="Rrule" valign="top">20</td><td styleCode="Rrule" valign="top">11</td><td styleCode="Rrule" valign="top">17.2</td><td styleCode="Rrule" valign="top">0.16 (0.10 &#x2013; 0.25)</td><td styleCode="Rrule" valign="top">1.58 (0.68 &#x2013; 3.66)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.